NAV-240 for Hidradenitis Suppurativa

(Mainsail Trial)

This trial tests a new treatment called NAV-240, an experimental therapy, to determine its effectiveness for individuals with moderate-to-severe hidradenitis suppurativa (HS), a skin condition causing painful bumps and tunnels under the skin. The goal is to assess whether NAV-240 reduces these inflamed skin bumps by 75% after 16 weeks compared to a placebo, an inactive treatment. Participants will receive either one of two doses of NAV-240 or a placebo through intravenous infusion. This trial may suit those who have had HS for at least six months, have at least five inflamed bumps, and have not responded well to antibiotics in the past. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial allows the use of certain oral antibiotics like doxycycline, minocycline, or tetracycline, but the dose must stay the same until Week 16. Topical antiseptics can also be used if you stick to one product throughout the study. Other medications are not specified, so it's best to discuss with the trial team.

Earlier research tested NAV-240 in healthy volunteers and found it safe and well tolerated, meaning most people did not experience serious side effects. Another study showed that NAV-240 can be administered once a month, indicating its long-lasting effects without causing issues.

Most treatments for hidradenitis suppurativa, like antibiotics and anti-inflammatory drugs, focus on reducing infection and inflammation. But NAV-240 works differently, targeting the underlying pathways that cause the skin lesions to form in the first place. Researchers are particularly excited because NAV-240 uses a novel mechanism of action that may offer more effective relief with fewer side effects. Additionally, the experimental doses of NAV-240 might provide tailored treatment options for varying severity levels of the condition, offering a more personalized approach to manage this challenging skin disorder.

Research suggests that NAV-240 might help treat hidradenitis suppurativa (HS) by targeting two important pathways in the body, OX40L and TNF-α. This dual-action method may reduce inflammation more effectively. Earlier studies have shown that NAV-240 can significantly decrease skin bumps, a common symptom of HS. In one study, participants experienced a noticeable reduction in inflamed areas without an increase in abscesses or draining tunnels. While these early results are promising, more research is needed to confirm them. Participants in this trial will receive either NAV-240 at one of two different doses or a placebo to further evaluate its effectiveness.¹²⁴⁶⁷